Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report details a specific share repurchase transaction executed on June 6, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 800,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,304 pence per share; lowest price paid was 1,289 pence per share.
- Treasury Shares Held: 499,174,284 shares (representing 8.83% of total issued share capital and 9.68% of total voting rights).
- Shares in Issue: 5,156,835,179 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's issued share capital through the cancellation of 800,000 repurchased shares. Consequently, the Company's Treasury shareholding now represents 8.83% of the total issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the 800,000 share repurchase based on the disclosed price range (1,289 to 1,304 pence).
- Confirm the updated total issued share capital and voting rights denominator (5,156,835,179 shares) for regulatory disclosure calculations.
- Note that the repurchased shares were cancelled rather than held indefinitely, reducing the total share count.